Summary
Platinum distribution was studied in rat peritoneal tumors after i.p. treatment with equimolar doses of carboplatin and cisplatin. Low platinum concentrations (4 ppm) were detected in the periphery of the tumor after carboplatin treatment, whereas no platinum was detected 0.5 mm in from the periphery. In contrast, after cisplatin treatment, high platinum concentrations (29 ppm) were measured in the periphery of the tumor and moderate concentrations (14 ppm) were measured in the center. Only following increased carboplatin doses were low platinum concentrations detectable in the tumor. The total platinum concentration in the tumors was determined after equimolar administration of both drugs. In all, 7 times more platinum was detected after cisplatin treatment than after carboplatin treatment, and 10 times more carboplatin than cisplatin had to be injected to obtain comparable platinum concentrations in the tumors. When single cells were incubated with equimolar concentrations of carboplatin and cisplatin, 6–7 times more platinum was found in cells treated with cisplatin. However, pharmacokinetic studies favored i.p. administration of carboplatin because the clearance of this compound from the peritoneal cavity, expressed ast 1/2β, was lower than that of cisplatin (239 vs 78 min), resulting in an AUC in the peritoneal cavity for both total and ultrafiltered drug that was almost 3 times higher for carboplatin than cisplatin. The AUC for ultrafiltered carboplatin in plasma was 2-fold that for cisplatin (2,801±210 vs 1,334±431 μM m). The present study demonstrated that in spite of the pharmacological advantages of carboplatin, its capacity to penetrate into peritoneal tumors and tumor cells is far lower than that of cisplatin.
Similar content being viewed by others
References
Booth BW, Weiss RB, Korzun AH, Wood WC, Carey RW, Panasci LC (1985) Phase II trials of carboplatin in advanced breast carcinoma: a cancer and leukemia group B study. Cancer Treat Rep 69: 919
Boven E, Van der Vijgh WJF, Nauta MM, Schluper HMM, Pinedo HM (1985) Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45: 86
Calvert AH, Harland SJ, Newell DR, Siddek ZH, Harrap KR (1985) Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12 [Suppl A]: 51
Canetta R, Rozencwieg M, Carter, SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12 [Suppl A]: 125
Clear MJ, Hydes PC, Malerbi BW, Watkins DM (1978) Anti-tumour platinum complexes: relationships between chemical properties and activity. Biochemie 60: 835
Colombo N, Speyer J, Werz J, Beckman EM, Beller U, Meyers M, Canetta R, Mugia FM (1987) Phase I–II study of intraperitoneal (ip) CBDCA in patients with ovarian cancer. Proc Am Soc Clin Oncol 6: 113
De Andres Basauri L, Lopez Pousa A, Alba E, Sampedro F (1986) Carboplatin, an active drug in advanced head and neck cancer. Cancer Treat Rep 70: 1173
Dedrick RL, Myers E, Bungay PM, De Vita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1
Dedrick RL, Flessner MF, Collins JM, Schultz JS (1986) A distributed model of peritoneal transport. In: Maher JF, Winchester JF (eds) Frontiers in peritoneal dialysis. Field, Rich and Associates, New York, p 31
DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI (1986) Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18: 235
Dikhoff TGMH, Prins M, Hofman LJB (1982) Target preparation of biological specimens for SPIXE measurements. Nucl Instrum Methods 197: 129
Dikhoff TGMH, Heide JA van der, Prins M, McVie JG (1983) The determination of platinum in human tissues with PIXE. IEEE Trans Nucl Sci 30: 1329
Dikhoff TGMH, Heide JA van der, McVie JG (1985) Topographic analysis of platinum levels in kidney slices from cisplatin treated patients. Nucl Instrum methods [B] 10/11: 639
Elferink F, Van der Vijgh WJF, Klein I, Vermorken JB, Gall HE, Pinedo HM (1988) Pharmacokinetics of diammine(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) after intravenous administration. Cancer Treat Rep 71: 1231
Elferink F, Van der Vijgh WJF, Klein I Ten Bokkel Huinink WW, Dubbelman R, McVie JG (1988) Pharmacokinetics of diammine(1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin) after intraperitoneal administration. Cancer Chemother Pharmacol 21: 57
Gibaldi M, Perrier D (1975) Pharmacokinetics. In: Swerbrick J (ed) Drugs and pharmaceutical sciences. vol. 1. Marcel Dekker, New York, p 45
Harrap KR (1985) Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12 [Suppl A]: 21
Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperiioncalcis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43: 1426
Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and stategies. J Natl Cancer Inst 81(8): 570
Johansson TB, Akselsson R, Johansson SAE (1970) X-ray analysis: elemental trace analysis at the 10 g level. Nucl Instrum Methods 84: 141
Kavanagh JJ, Nicaise C (1989) Carboplatin in refractory epithelial ovarian cancer. Semin Oncol 16(2) [Suppl 5]: 45
Kerr DJ, Kaye SB (1987) Aspects of cytotoxic drug penetration with particular reference to anthracyclines. Cancer Chemother Pharmacol 19: 1
Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence thatcis-diamminedichloroplatinum(II) andcis-diammine(1,1-cyclobutane dicarboxylo)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46: 1972
Lelieveld P, Van der Vijgh WJF, Veldhuizen RW, Van Velzen D, Van Putten LM, Atassi G, Danguy A (1984) Preclinical studies on toxicity, antitumor activity and pharmacokinetics of cisplatin and three recently developed derivates. Eur J Cancer Clin Oncol 20: 1087
Los G, Mutsaers PHA, Vijgh WJF van der, Hamer CJA van der, McVie JG (1987) Platinum distribution in intraperitoneal tumors after intraperitoneal or intravenous chemotherapy. Proc Am Assoc Clin Oncol 6: 42
Los G, Mutsaers PHA, Vijgh WJF van der, Baldew GS, Graaf PW de, McVie JG (1989) Direct diffusion ofcis-diamminedichloroplatinum(II) in intraperitoneal tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380
Los G, Ruevekamp M, Bosnie N, Graaf PW de, McVie JG (1989) Intraperitoneal tumor growth an chemotherapy in a rat model. Eur J Cancer Clin Oncol 25: 1857
Los G, Mutsaers PHA, Lenglet WJM, Baldew GS, McVie JG (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25: 389
Lum BL, DeGregorio MW, Holleran WM, DaRoza R, Brown M, Schiffman R, Jacobs CD, Lewis RL, Halsey J, Scudder SA, Sikic BI (1986) The clinical pharmacology of intraperitoneal carboplatin: a phase I/II study of the Northern California Oncology Group. Proc Am Soc Clin Oncol 5: 50
McVie JG, Ten Bokkel Huinink W, Dubbelman R, Franklin H, Vijgh WJF van der, Klein I (1985) Phase I study and pharmacokinetics of intraperitoneal carboplatin. Cancer Treat Rev 12 [Suppl A]: 35
Neijt JP, Van der Burg MEL, Vriesekoop R, Van Lindert AMC, Van Lent M, Ten Bokkel Huinink WW, Van Oosterom AT, Kooyman CD, Hamerlynck JVTH, Van Houwelingen JC, Pinedo HM (1984) Randomized trial comparing two combination chemotherapy regimens (HEXA-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet II: 594
Pfeiffer P, Bennedbaek O, Bertelsen K (1990) Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 36: 306
Siddik ZH, Dible SE, Boxall FE, Harrap KR (1986) Renal pharmacokinetics and toxicity of cisplatin and carboplatin in animals. In: McBrien DC, Slater TF (eds) Biochemical mechanisms of platinum antitumour drugs. IRL Press, Oxford, p 355
Siddik ZH, Jones M, Boxall FE, Harrap KR (1988) Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 21: 19
Sternberg C, Kelsen D, Dukeman M, Leichman L, Heelan R (1985) Carboplatin: a new platinum analog in he treatment of epidermoid carcinoma of the esophagus. Cancer Treat Rep 69: 1305
Ten Bokkel Huinink WW, Dubbelman R, Aartsen E Franklin H, McVie JG (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12 [Suppl 4]: 43
Ten Bokkel Huinink WW, Burg MEL van den, Oosterom AT van, Vermorken JB, Veenhof C, Roosendaal K (1985) A pilot study of CHAC-1. Cancer Treat Rev 12 [Suppl A]: 77
Ten Bokkel Huinink WW, Heintz APM, Dubbelman R, Franklin H, McVie JG (1988) Intraperitoneal carboplatin for refractory ovarian cancer: a phase I study. Proceedings of the 2nd International Conference on Intracavitary Chemotherapy, San Diego, p 47, February 24–27
Wilshaw E (1985) Ovarian trial at the Royal Marsden. Cancer Treat Rev 12 [Suppl A]: 67
Zedick MS, Sternberg SS (1974) A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate. J Natl Cancer Inst 53: 1419
Author information
Authors and Affiliations
Additional information
This work was supported by grant NKI 86-5 from the Dutch Cancer Society
Rights and permissions
About this article
Cite this article
Los, G., Verdegaal, E.M.E., Mutsaers, P.H.A. et al. Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28, 159–165 (1991). https://doi.org/10.1007/BF00685503
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685503